At Axial, we are at the forefront of scientific innovation in the gut microbiome and its intersection with neurodegenerative diseases and neurodevelopmental disorders. We are dedicated to improving the lives of people with conditions such as Autism Spectrum Disorder and Parkinson’s disease by leveraging our understanding of the role of the microbiome and its impact on the nervous system to providing Microbial Inspired Therapeutics research and development, medical applications, and pharmaceuticals.
SM
Axial Therapeutics Biotechnology Company
Axial’s novel therapeutic approach is focused on the development of small molecule drugs with defined mechanisms of action that act on new targets in the gut to mitigate the impact of metabolites and bacteria linked to the pathology, progression, and symptoms of neurological diseases and disorders.
